Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03582033
Recruitment Status : Recruiting
First Posted : July 10, 2018
Last Update Posted : July 13, 2021
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

Brief Summary:

This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur.

The study will have three parts. In the first part, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works.

In the second part of the study, participants will get SEA-BCMA and dexamethasone. In the third part, participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the study will find out whether these drugs are safe when used together.


Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: SEA-BCMA Drug: dexamethasone Drug: pomalidomide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 225 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Actual Study Start Date : November 1, 2018
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: SEA-BCMA Monotherapy
SEA-BCMA
Drug: SEA-BCMA
Given into the vein (IV; intravenously)

Experimental: SEA-BCMA + Dexamethasone Combination Therapy
SEA-BCMA + dexamethasone
Drug: SEA-BCMA
Given into the vein (IV; intravenously)

Drug: dexamethasone
Given by mouth (orally) or by IV

Experimental: SEA-BCMA + Pomalidomide/Dexamethasone Combination Therapy
SEA-BCMA + dexamethasone + pomalidomide
Drug: SEA-BCMA
Given into the vein (IV; intravenously)

Drug: dexamethasone
Given by mouth (orally) or by IV

Drug: pomalidomide
Given orally




Primary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: Through 30-37 days following last dose, up to approximately 3 years ]
    AE grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant but not immediately life-threatening; Grade 4 - life-threatening consequences; Grade 5 - death related to AE

  2. Number of participants with laboratory abnormalities by grade [ Time Frame: Through 30-37 days following last dose, up to approximately 3 years ]
    Grades for laboratory abnormalities will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03

  3. Incidence of dose-limiting toxicities (DLTs) [ Time Frame: Through up to 28 days following first dose ]

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) outcome: Cmax (maximum serum concentration) [ Time Frame: Through 30-37 days following last dose, up to approximately 3 years ]
  2. PK outcome: AUC (area under the serum concentration-time curve) [ Time Frame: Through 84 days following first dose ]
  3. Incidence of SEA-BCMA antitherapeutic antibodies (ATA) [ Time Frame: Through 30-37 days following last dose, up to approximately 3 years ]
  4. Best response per the IMWG uniform response criteria [ Time Frame: Up to approximately 4 years ]
    International Myeloma Working Group (IMWG)

  5. Objective response rate (ORR) [ Time Frame: Up to approximately 4 years ]
    The proportion of patients with stringent complete response, complete response, very good partial response, or partial response per investigator

  6. Duration of objective response (OR) [ Time Frame: Up to approximately 4 years ]
    The time from first documentation of OR to the first documentation of disease progression or death due to any cause

  7. Duration of complete response (CR) [ Time Frame: Up to approximately 4 years ]
    The time from first documentation of CR to the first documentation of disease progression or death due to any cause

  8. Progression-free survival (PFS) [ Time Frame: Up to approximately 4 years ]
    The time from the start of study treatment to the first documentation of disease progression or death due to any cause

  9. Overall survival (OS) [ Time Frame: Up to approximately 4 years ]
    The time from the start of study treatment to the date of death due to any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of MM
  • Must have MM that is relapsed or refractory
  • Has received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
  • Measurable disease, as defined by at least one of the following: (1) serum M protein 0.5 g/dL or higher, (2) urine M protein 200 mg/24 hour or higher, and (3) serum immunoglobulin free light chain (FLC) 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1
  • Life expectancy of greater than 3 months in the opinion of the investigator
  • Adequate hematologic, renal, and hepatic function

Exclusion Criteria:

  • Prior treatment with a BCMA-directed therapy
  • History of another malignancy within 3 years
  • Active cerebral or meningeal disease related to the underlying malignancy
  • Uncontrolled Grade 3 or higher infection
  • Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR-T-cell therapy must be completed 8 weeks before first dose of study drug.
  • Combination therapy only:

    1. Known intolerance to corticosteroids
    2. Uncontrolled psychoses

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03582033


Contacts
Layout table for location contacts
Contact: Seagen Trial Information Support 866-333-7436 clinicaltrials@seagen.com

Locations
Layout table for location information
United States, California
Stanford University School of Medicine Recruiting
Palo Alto, California, United States, 94304
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Michaela Liedtke         
United States, Colorado
Rocky Mountain Cancer Centers - Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Robert Rifkin         
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: James Hoffman         
United States, Iowa
Holden Comprehensive Cancer Center / University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Michael Tomasson         
United States, Kansas
University of Kansas Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Al-Ola Abdallah, MD         
United States, Missouri
Washington University in St Louis Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Mark Schroeder         
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Ruben Niesvizky         
James P. Wilmot Cancer Center / University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14642
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Brea Lipe         
United States, Oregon
Willamette Valley Cancer Institute/Oncology Assc of Oregon Recruiting
Eugene, Oregon, United States, 97401
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Christopher Yasenchak         
United States, Texas
Texas Oncology - Austin Midtown Recruiting
Austin, Texas, United States, 78705
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Jason Melear         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109-1024
Contact: Seagen Trial Information Support    866-333-7436    clinicaltrials@seagen.com   
Principal Investigator: Damian Green, MD         
Sponsors and Collaborators
Seagen Inc.
Investigators
Layout table for investigator information
Study Director: Phoenix Ho, MD Seagen Inc.
Layout table for additonal information
Responsible Party: Seagen Inc.
ClinicalTrials.gov Identifier: NCT03582033    
Other Study ID Numbers: SGNBCMA-001
First Posted: July 10, 2018    Key Record Dates
Last Update Posted: July 13, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Seagen Inc.:
RRMM
Antibodies, monoclonal
Antigens, BCMA
Immunotherapy
Hematologic diseases
Myeloma
Seattle Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Pomalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents